Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

HAV IgM ELISA Kit

HAV IgM Reactivity: Hepatitis A Virus (HAV) Colorimetric Competition ELISA Serum
Catalog No. ABIN997031
  • Target See all HAV IgM products
    HAV IgM (Anti-Hepatitis A Virus Antibody IgM (HAV IgM))
    Reactivity
    Hepatitis A Virus (HAV)
    Detection Method
    Colorimetric
    Method Type
    Competition ELISA
    Application
    ELISA
    Purpose
    The HAV IgM ELISA test is an enzyme-linked immunosorbent assay (ELISA) which is used for the qualitative determination of IgM-class antibodies to hepatitis A virus in human serum/plasma.
    Sample Type
    Serum
    Analytical Method
    Qualitative
    Specificity
    100%
    Sensitivity
    100%
  • Sample Volume
    100 μL
    Assay Time
    1 - 2 h
    Plate
    Pre-coated
    Restrictions
    For Research Use only
  • Storage
    4 °C
    Expiry Date
    12-18 months
  • Target See all HAV IgM products
    HAV IgM (Anti-Hepatitis A Virus Antibody IgM (HAV IgM))
    Alternative Name
    HAV IgM (HAV IgM Products)
    Target Type
    Antibody
    Background
    Hepatitis A is a self-limited disease and chronic stage or other complications are rare. Infections occur early in life in areas where sanitation is poor and living conditions are crowded. With improved sanitation and hygiene, infections are delayed and consequently the number of persons susceptible to the disease increases. Because the disease is transmitted through the fecal-oral route in dense populated regions, an outbreak can arise from single contaminated source. The cause of hepatitis A is hepatitis A virus (HAV)-non enveloped positive strand RNA virus with a linear single strand genome, encoding for only one known serotype.

    HAV has four major, structural polypeptides and it localizes exclusively in the cytoplasm of human hepatocytes. The infection with HAV induces strong immunological response and elevated levels first of IgM and then IgG are detectable within a few days after the onset of the symptoms. The presence of anti–HAV IgM is an important serological marker for early detection and observation of the clinical manifestation of the disease. Increasing levels of anti-HAV IgM are detectable about three weeks after exposure with highest titter after four to six weeks later. Within six months after infection IgM concentration declines to non-detectable levels.
You are here:
Support